Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000543568 | SCV000640808 | likely benign | Nemaline myopathy 2 | 2024-01-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004586774 | SCV005076785 | likely benign | not specified | 2024-04-10 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.5031+4T>C alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 7.4e-05 in 1609430 control chromosomes in the gnomAD database, including 1 homozygotes. To our knowledge, no occurrence of c.5031+4T>C in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 465610). Based on the evidence outlined above, the variant was classified as likely benign. |
Natera, |
RCV000543568 | SCV001453498 | likely benign | Nemaline myopathy 2 | 2020-09-16 | no assertion criteria provided | clinical testing |